Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 6/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | Q9HBH1 | 1/20 | 0.34 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29696200 | 1.00 | CA2 (0.42) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL66398 | 1.00 | CA2 (0.42) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL31407436 | 0.95 | GRIK1 (0.41) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL8460619 | 0.95 | GRIK1 (0.41) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL25177958 | 0.94 | GRIK1 (0.43) | CA2SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL66573 | 0.90 | HDAC1 (0.41) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL20826464 | 0.90 | HDAC1 (0.41) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL67491 | 0.90 | HDAC1 (0.41) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL27041531 | 0.87 | MEN1 (0.37) | MEN1GAAKMT2AMMP13 | |
| SCHEMBL27041525 | 0.87 | MEN1 (0.37) | MEN1GAAKMT2AMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053044-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | UNIV EMORY (US) | 2021-02-25 | — | — | US | disclosed |
| US-20180318818-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | EMORY UNIVERSITY (US) | 2018-11-08 | — | — | US | disclosed |
| CN-107935988-A | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2018-04-20 | — | — | CN | disclosed |
| EP-3057948-B1 | SELECTIVELY SUBSTITUTED QUINOLINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2018-03-14 | — | — | EP | disclosed |
| CN-105636945-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2017-11-17 | — | — | CN | disclosed |
| US-9700881-B2 | Heterocyclic coupling catalysts and methods related thereto | EMORY UNIVERSITY (US) | 2017-07-11 | — | — | US | disclosed |
| US-9663486-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| WO-2017070157-A1 | REDOX DEHYDRATION COUPLING CATALYSTS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20160243534-A1 | Heterocyclic Coupling Catalysts and Methods Related Thereto | EMORY UNIVERSITY (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160176841-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
| CN-105636945-A | Optionally substituted quinoline compounds | EISAI R&D MAN CO LTD | 2016-06-01 | — | — | CN | disclosed |
| WO-2015054337-A1 | HETEROCYCLIC COUPLING CATALYSTS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2015-04-16 | — | — | WO | disclosed |
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| CN-102292319-A | Novel substituted octahydrocyclopenta(C)pyrrol-4-amines as calcium channel blockers | — | 2011-12-21 | — | — | CN | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2367790-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010062927-A2 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176841-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | CA2 3834/4885MAPK1 1935/4885SLC1A2 1899/4885 |
| US-20160243534-A1 | Heterocyclic Coupling Catalysts and Methods Related Thereto | HAT1, CBR3, CBR1 | CA2 1796/4885MAPK1 3499/4885SLC1A2 2741/4885 |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CA2 138/4885MAPK1 1472/4885SLC1A2 234/4885 |
| US-20180318818-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | SCLY, TST, SELENOI | CA2 476/4885MAPK1 3124/4885SLC1A2 1498/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CA2 138/4885MAPK1 1472/4885SLC1A2 234/4885 |
| US-20210053044-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | SCLY, TST, SQOR | CA2 452/4885MAPK1 3296/4885SLC1A2 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.